Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Biosimilar rituximab (SAIT101)
print preview
bookmark
share with colleague
General Information
Company
Samsung BioLogics
Description
Biosimilar or rituximab, a chimeric mAb against CD20 antigen
Molecular Target
CD20
Mechanism of Action
Antibody
Latest Stage of Development
Phase III
Indication
Rheumatoid arthritis (RA)
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information